Ocugen doses first patient in Phase 3 OCU410 gene therapy trial for geographic atrophy
Ocugen has begun the 237-patient Phase 3 ArMaDa3 trial of OCU410, a one-time gene therapy for geographic atrophy after Phase 2 treatment reduced lesion growth by 31% at 12 months.